Management of cutaneous AEs
pruritus, erythema, ulcerative or bullous dermatitis, rash/dermatitis
EVENT, ERYTHEMA, ERUPTION, VESICULAR ERUPTION, GENERALIZED ERYTHRODERMA
Guidance for the management of rash/dermatitis was included in the trial protocol, in line with the stepwise approach proposed by Song et al.In the event of grade 2 macular or papular eruption, erythema with pruritus or other associated symptoms, localized desquamation or other lesions covering less than 50% of body surface area (BSA), tovorafenib dose reduction by one dose level once weekly could be considered. In the event of grade 3 or higher severe, generalized erythroderma or macular, papular or vesicular eruption, desquamation covering ≥50% of BSA or generalized exfoliative, ulcerative or bullous dermatitis, tovorafenib dosing was to be delayed until the condition improved, a dermatologist was consulted and a dose reduction by two dose levels or holding tovorafenib administration until resolution to grade 1 or baseline could be considered.